Susanna Y. Cheng

机构：Sunnybrook Health Science Centre, Health Sciences Centre

发表论文 42 篇 · 总被引 8378 次 · h-index 14

代表论文

• Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 (2021 · Annals of Oncology · 被引 426)
• Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions (2023 · New England Journal of Medicine · 被引 375)
• Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial (2020 · The Lancet Oncology · 被引 220)
• FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189 (2021 · Journal of Thoracic Oncology · 被引 39)
• Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). (2020 · Journal of Clinical Oncology · 被引 25)
• Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study (2019 · Cancer Research · 被引 23)